KAMES CAPITAL plc decreased its stake in Pfizer, Inc. (NYSE:PFE) by 11.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 974,851 shares of the biopharmaceutical company’s stock after selling 127,169 shares during the period. KAMES CAPITAL plc’s holdings in Pfizer were worth $33,340,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Asset Planning Services Ltd. increased its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 137 shares in the last quarter. Orrstown Financial Services Inc. boosted its position in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 612 shares during the last quarter. Cable Hill Partners LLC boosted its position in Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 265 shares during the last quarter. D Orazio & Associates Inc. boosted its position in Pfizer by 0.5% in the fourth quarter. D Orazio & Associates Inc. now owns 5,223 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 28 shares during the last quarter. Finally, Acropolis Investment Management LLC boosted its position in Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 100 shares during the last quarter. 69.98% of the stock is owned by institutional investors and hedge funds.

Shares of Pfizer, Inc. (NYSE:PFE) opened at 33.32 on Tuesday. The company’s 50 day moving average is $33.24 and its 200-day moving average is $33.25. The firm has a market cap of $198.85 billion, a PE ratio of 28.05 and a beta of 1.01. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $37.39.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, beating the Zacks’ consensus estimate of $0.67 by $0.02. The business had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. Pfizer’s revenue for the quarter was down 1.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Equities research analysts predict that Pfizer, Inc. will post $2.55 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.84%. The ex-dividend date is Wednesday, August 2nd. Pfizer’s payout ratio is 108.48%.

TRADEMARK VIOLATION WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.dailypolitical.com/2017/07/25/pfizer-inc-nysepfe-stake-decreased-by-kames-capital-plc.html.

Several equities analysts recently commented on the stock. Jefferies Group LLC reiterated a “hold” rating and set a $35.00 target price (up from $34.00) on shares of Pfizer in a research note on Friday, July 14th. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, July 10th. Sanford C. Bernstein set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, July 17th. BidaskClub cut shares of Pfizer from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 13th. Finally, Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and cut their target price for the company from $38.00 to $36.00 in a research note on Thursday, July 20th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $37.68.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.